Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. - Wikidata - wikimedia - TriplyDB

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

http://www.wikidata.org/entity/Q34626688

about

Chemotherapeutic drug targeting to lungs by way of microspheres after intravenous administration

P2860

Q57073601-F305D91A-41AC-4AEA-ACA0-5E00362B02B7

P2860

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

http://www.wikidata.org/entity/Q34626688

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@ast

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@en

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@nl

type

label

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@ast

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@en

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@nl

prefLabel

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@ast

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@en

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@nl

P1433

Q34626688-4C3F1420-FC07-47CA-8063-E0D56E61FD55

P1476

Q34626688-E6FC6F38-515B-4AB3-A9E4-4A14E37A00D7

P2093

Q34626688-1D4D9A09-B31E-425E-B267-81ACC1924C5B

Q34626688-4289EF68-448D-4F46-B74F-83B3EC80BBD5

Q34626688-6252CD48-E528-4BB4-BE98-EA0AE663CD0A

Q34626688-A5777F29-A257-4BD0-9FB7-B6BE915C6E91

Q34626688-C50127B9-9CAD-4F0E-A8BD-CE54EA170D41

Q34626688-E8F348DC-C944-4950-A6AB-701A14173932

Q34626688-EB0BE243-7ABF-47BD-8674-3587FBA8DE14

Q34626688-ECAEDD6B-5665-49EE-9DED-4506C807ED65

P2860

Q34626688-03EBA7D7-88C4-4468-AF8C-F6F4A088C6B5

Q34626688-122EEADF-E7A3-43D9-B4B2-BF8A377E0B02

Q34626688-144D09B1-4149-466F-BB56-D823431E0219

Q34626688-17F29D63-A3EB-4B8C-A2E1-B18BB38C7273

Q34626688-1D19BC79-2264-48F3-9E31-E7A0E029257F

Q34626688-1E1B6E78-1821-4E5D-9F14-EEFDFDCCA293

Q34626688-2312F3AB-66C0-4A51-AF14-E03FAA55CEE6

Q34626688-244279ED-7D42-4679-B9CA-D42658DE6A79

Q34626688-2838D82F-E9A5-47FF-B715-354B89E20D1B

Q34626688-2E621045-E6E3-43AC-9B9D-E2F5EE1F54BB

P304

Q34626688-5308A649-D369-4F1F-AC7E-24ED7418EF0B

P31

Q34626688-C412C07A-C4EA-4DB9-8677-64529C08FE86

P356

Q34626688-9A910B68-8BAF-40D2-BAE6-3CEF4C7FCFE9

P407

Q34626688-910966F1-1828-4ADC-9F18-1B4E1B847558

P433

Q34626688-6C0656C7-BDCB-4F28-A759-5BAFD46202A1

P478

Q34626688-A7EF3C54-6281-41E9-8B0D-2F5D0B083EDA

P577

Q34626688-5B20DCD7-CEDD-4FE1-B868-623070EE2F2F

P5875

Q34626688-B2ECAACD-F13D-4039-83A0-E7D073649EBD

P698

Q34626688-E227D65E-4611-4E14-806F-DC0BCEA8BEBB

P356

P1433

P1476

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.

@en

P2093

Alice De Sanctis

http://www.w3.org/2001/XMLSchema#string

David Khayat

http://www.w3.org/2001/XMLSchema#string

Giorgio Vittorio Scagliotti

http://www.w3.org/2001/XMLSchema#string

Jean Philippe Spano

http://www.w3.org/2001/XMLSchema#string

Laurent Taillade

http://www.w3.org/2001/XMLSchema#string

Rosa Conforti

http://www.w3.org/2001/XMLSchema#string

Silvia Novello

http://www.w3.org/2001/XMLSchema#string

Stephane Vignot

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Diagnosis and management of drug-associated interstitial lung disease

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Management and preparedness for infusion and hypersensitivity reactions.

[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.

Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.

High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.

A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.

P304

3069-3080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25894

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49800964

http://www.w3.org/2001/XMLSchema#string

P698

21283982

http://www.w3.org/2001/XMLSchema#string